Economists and physicians have thoroughly studied the effects of FDA boxed warnings on prescription patterns. It is not necessarily true that a physician and patient will have a conversation about a drug's boxed warning after it is issued.  For instance, an FDA-mandated boxed warning decreased rosiglitazone use by 70%, but that still meant million people were given the drug. Later research indicated that after receiving an FDA advisory, there was a decrease in rosiglitazone use, due to a combined effect of media exposure, advisory, and scientific publications, whereas pioglitazone (with a similar advisory but less media exposure) did not similarly decrease in use.  This challenges the idea that physicians and patients will have a conversation after a boxed warning is issued. [ clarification needed ] Throughout the country, boxed warnings will be translated into prescription patterns differently by different physicians.